Literature DB >> 26283726

Whole-Body In Vivo Monitoring of Inflammatory Diseases Exploiting Human Interleukin 6-Luciferase Transgenic Mice.

Makiko Hayashi1, Jun Takai1, Lei Yu1, Hozumi Motohashi2, Takashi Moriguchi3, Masayuki Yamamoto3.   

Abstract

Chronic inflammation underlies the pathological progression of various diseases, and thus many efforts have been made to quantitatively evaluate the inflammatory status of the diseases. In this study, we generated a highly sensitive inflammation-monitoring mouse system using a bacterial artificial chromosome (BAC) clone containing extended flanking sequences of the human interleukin 6 gene (hIL6) locus, in which the luciferase (Luc) reporter gene is integrated (hIL6-BAC-Luc). We successfully monitored lipopolysaccharide-induced systemic inflammation in various tissues of the hIL6-BAC-Luc mice using an in vivo bioluminescence imaging system. When two chronic inflammatory disease models, i.e., a genetic model of atopic dermatitis and a model of experimental autoimmune encephalomyelitis (EAE), were applied to the hIL6-BAC-Luc mice, luciferase bioluminescence was specifically detected in the atopic skin lesion and central nervous system, respectively. Moreover, the Luc activities correlated well with the disease severity. Nrf2 is a master transcription factor that regulates antioxidative and detoxification enzyme genes. Upon EAE induction, the Nrf2-deficient mice crossed with the hIL6-BAC-Luc mice exhibited enhanced neurological symptoms concomitantly with robust luciferase luminescence in the neuronal tissue. Thus, whole-body in vivo monitoring using the hIL6-BAC-Luc transgenic system (WIM-6 system) provides a new and powerful diagnostic tool for real-time in vivo monitoring of inflammatory status in multiple different disease models.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26283726      PMCID: PMC4573709          DOI: 10.1128/MCB.00506-15

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  32 in total

Review 1.  IL6 and the acute phase reaction.

Authors:  J Gauldie; C Richards; H Baumann
Journal:  Res Immunol       Date:  1992-09

2.  Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys.

Authors:  M Innes Asher; Stephen Montefort; Bengt Björkstén; Christopher K W Lai; David P Strachan; Stephan K Weiland; Hywel Williams
Journal:  Lancet       Date:  2006-08-26       Impact factor: 79.321

3.  Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema.

Authors:  Yukio Ishii; Ken Itoh; Yuko Morishima; Toru Kimura; Takumi Kiwamoto; Takashi Iizuka; Ahmed E Hegab; Tomonori Hosoya; Akihiro Nomura; Tohru Sakamoto; Masayuki Yamamoto; Kiyohisa Sekizawa
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

Review 4.  Interleukin-6: from basic science to medicine--40 years in immunology.

Authors:  Tadamitsu Kishimoto
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 5.  Risk factors for asthma and atopy.

Authors:  L Karla Arruda; Dirceu Solé; Carlos E Baena-Cagnani; Charles K Naspitz
Journal:  Curr Opin Allergy Clin Immunol       Date:  2005-04

6.  An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.

Authors:  K Itoh; T Chiba; S Takahashi; T Ishii; K Igarashi; Y Katoh; T Oyake; N Hayashi; K Satoh; I Hatayama; M Yamamoto; Y Nabeshima
Journal:  Biochem Biophys Res Commun       Date:  1997-07-18       Impact factor: 3.575

7.  Constitutive expression of aryl hydrocarbon receptor in keratinocytes causes inflammatory skin lesions.

Authors:  Masafumi Tauchi; Azumi Hida; Takaaki Negishi; Fumiki Katsuoka; Shuhei Noda; Junsei Mimura; Tomonori Hosoya; Akinori Yanaka; Hiroyuki Aburatani; Yoshiaki Fujii-Kuriyama; Hozumi Motohashi; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

Review 8.  Nrf2-Keap1 defines a physiologically important stress response mechanism.

Authors:  Hozumi Motohashi; Masayuki Yamamoto
Journal:  Trends Mol Med       Date:  2004-11       Impact factor: 11.951

9.  Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis.

Authors:  Rajesh K Thimmulappa; Hannah Lee; Tirumalai Rangasamy; Sekhar P Reddy; Masayuki Yamamoto; Thomas W Kensler; Shyam Biswal
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

10.  Real-time monitoring of stress erythropoiesis in vivo using Gata1 and beta-globin LCR luciferase transgenic mice.

Authors:  Mikiko Suzuki; Kinuko Ohneda; Sakie Hosoya-Ohmura; Saho Tsukamoto; Osamu Ohneda; Sjaak Philipsen; Masayuki Yamamoto
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

View more
  15 in total

1.  Nrf2 represses the onset of type 1 diabetes in non-obese diabetic mice.

Authors:  Yoko Yagishita; Akira Uruno; Dionysios V Chartoumpekis; Thomas W Kensler; Masayuki Yamamoto
Journal:  J Endocrinol       Date:  2019-01-01       Impact factor: 4.286

2.  Reducing Inflammatory Cytokine Production from Renal Collecting Duct Cells by Inhibiting GATA2 Ameliorates Acute Kidney Injury.

Authors:  Lei Yu; Takashi Moriguchi; Hiroshi Kaneko; Makiko Hayashi; Atsushi Hasegawa; Masahiro Nezu; Hideyuki Saya; Masayuki Yamamoto; Ritsuko Shimizu
Journal:  Mol Cell Biol       Date:  2017-10-27       Impact factor: 4.272

3.  Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation.

Authors:  Nadine Keleku-Lukwete; Mikiko Suzuki; Akihito Otsuki; Kouhei Tsuchida; Saori Katayama; Makiko Hayashi; Eriko Naganuma; Takashi Moriguchi; Osamu Tanabe; James Douglas Engel; Masue Imaizumi; Masayuki Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-14       Impact factor: 11.205

Review 4.  HSC Aging and Senescent Immune Remodeling.

Authors:  Michael D Denkinger; Hanna Leins; Reinhold Schirmbeck; Maria Carolina Florian; Hartmut Geiger
Journal:  Trends Immunol       Date:  2015-11-21       Impact factor: 16.687

Review 5.  Environmental pollutants and the immune response.

Authors:  Takafumi Suzuki; Takanori Hidaka; Yoshito Kumagai; Masayuki Yamamoto
Journal:  Nat Immunol       Date:  2020-10-12       Impact factor: 25.606

6.  NRF2: KEAPing Tumors Protected.

Authors:  Ray Pillai; Makiko Hayashi; Anastasia-Maria Zavitsanou; Thales Papagiannakopoulos
Journal:  Cancer Discov       Date:  2022-03-01       Impact factor: 38.272

Review 7.  Outstanding animal studies in allergy II. From atopic barrier and microbiome to allergen-specific immunotherapy.

Authors:  Erika Jensen-Jarolim; Isabella Pali-Schöll; Franziska Roth-Walter
Journal:  Curr Opin Allergy Clin Immunol       Date:  2017-06

Review 8.  Outstanding animal studies in allergy I. From asthma to food allergy and anaphylaxis.

Authors:  Erika Jensen-Jarolim; Isabella Pali-Schöll; Franziska Roth-Walter
Journal:  Curr Opin Allergy Clin Immunol       Date:  2017-06

9.  Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription.

Authors:  Eri H Kobayashi; Takafumi Suzuki; Ryo Funayama; Takeshi Nagashima; Makiko Hayashi; Hiroki Sekine; Nobuyuki Tanaka; Takashi Moriguchi; Hozumi Motohashi; Keiko Nakayama; Masayuki Yamamoto
Journal:  Nat Commun       Date:  2016-05-23       Impact factor: 14.919

Review 10.  Linking Activation of Microglia and Peripheral Monocytic Cells to the Pathophysiology of Psychiatric Disorders.

Authors:  Yuta Takahashi; Zhiqian Yu; Mai Sakai; Hiroaki Tomita
Journal:  Front Cell Neurosci       Date:  2016-06-03       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.